Nussbaum Ran 4

What Happened

• Ran Nussbaum, a director of LB Pharmaceuticals, was granted a derivative award covering 10,000 shares reported on Form 4 for a June 3, 2026 transaction. The filing shows an acquisition price of $0.00 (derivative award code A). This was a grant/award rather than an open-market purchase or sale, so it is a compensation-related issuance rather than a direct cash investment or exit.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 5, 2026 (timely filing).
• Nature: Derivative award/grant (code A) for 10,000 shares; reported price $0.00.
• Vesting: Footnote states 100% of the shares underlying the award vest on the earlier of (i) June 3, 2027 or (ii) the date of the issuer’s next annual meeting, subject to continuous service through vesting.
• Shares owned after transaction: Not specified in this Form 4.
• Filing accession: 0001609805-26-000003.

Context

• This is a compensation award to a director; such grants are common and depend on future vesting/service conditions. The $0.00 price on the Form 4 reflects how the award was reported; consult the company’s proxy or press release for complete details on award type (e.g., RSUs vs. options) and any exercise price or value. This transaction is informational and does not by itself indicate buying or selling sentiment.